Cross-Sector entity
Sera Prognostics is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in medical-devices, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention PRIME study, all published on March 19, 2026.
2 verified stories tracked
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Sera Prognostics is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Coverage clusters in medical-devices, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Cross-Sector stories that mention PRIME study, all published on March 19, 2026. Each carries 6 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering PRIME study. Shared-story counts are live from our verified record — not editorial picks.
Runway Horizon
Current capital projected to fund operations through significant commercial milestones.
Cash Runway Limit
Current capital projected to fund operations through this period across commercial milestones.
2026 Target
Goal to reach 15-17 states and operate 5-7 live partner programs.
Q4 Earnings Call
Management outlines pivot from R&D to commercial scaling and state-level engagement.
Fiscal Year End
Sera concludes 2025 with $95.8M cash and successful PRIME study publication.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.
